Printer Friendly

AFFYMAX AND ALZA SIGN DEFINITIVE AGREEMENT FOR JOINT DEVELOPMENT PROGRAM

 PALO ALTO, Calif., July 29 /PRNewswire/ -- Affymax Research Institute and ALZA Corp. signed a definitive agreement to establish a pharmaceutical development program under which Affymax is applying its proprietary chemistries to modify currently marketed drugs, or drugs in late stages of clinical development, for use with ALZA's electrotransport technology. The companies have been working under an agreement in principle since November 1991.
 Affymax N.V. (NASDAQ: AFMXF) is developing new technologies to accelerate the pace of drug discovery. Affymax is applying these technologies across a broad range of diseases to discover and develop products independently and in collaboration with established pharmaceutical companies. The majority of the company's research and development activities are performed by its wholly owned subsidiary, Affymax Research Institute, located in Palo Alto and Santa Clara.
 -0- 7/29/93
 /CONTACT: Diana E. Kapp of Affymax, 415-496-2300/
 (AFMXF)


CO: Affymax Research Institute; ALZA Corp.; Affymax N.V. ST: California IN: MTC SU: JVN

LH-GT -- SJ004 -- 7114 07/29/93 08:38 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 29, 1993
Words:164
Previous Article:APPLE ANNOUNCES THE INTRODUCTION OF THE FIRST COMPUTER DISPLAY WITH INTEGRATED AUDIO AND VIDEO CAPABILITIES
Next Article:AFFIRM VPIII MICROBIAL IDENTIFICATION SYSTEM INTRODUCED BY MICROPROBE: SIMULTANEOUS DETECTION OF 3 VAGINITIS PATHOGENS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters